Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.59
ABT's Cash to Debt is ranked higher than
58% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. ABT: 0.59 )
ABT' s 10-Year Cash to Debt Range
Min: 0.05   Max: 1.23
Current: 0.59

0.05
1.23
Equity to Asset 0.54
ABT's Equity to Asset is ranked higher than
62% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ABT: 0.54 )
ABT' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.59
Current: 0.54

0.37
0.59
Interest Coverage 16.75
ABT's Interest Coverage is ranked higher than
54% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 241.11 vs. ABT: 16.75 )
ABT' s 10-Year Interest Coverage Range
Min: 4.91   Max: 43.12
Current: 16.75

4.91
43.12
F-Score: 5
Z-Score: 3.72
M-Score: -2.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 13.27
ABT's Operating margin (%) is ranked higher than
87% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. ABT: 13.27 )
ABT' s 10-Year Operating margin (%) Range
Min: 9.09   Max: 24.99
Current: 13.27

9.09
24.99
Net-margin (%) 8.52
ABT's Net-margin (%) is ranked higher than
84% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. ABT: 8.52 )
ABT' s 10-Year Net-margin (%) Range
Min: 7.64   Max: 20.27
Current: 8.52

7.64
20.27
ROE (%) 8.29
ABT's ROE (%) is ranked higher than
79% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. ABT: 8.29 )
ABT' s 10-Year ROE (%) Range
Min: 9.93   Max: 43.56
Current: 8.29

9.93
43.56
ROA (%) 4.63
ABT's ROA (%) is ranked higher than
79% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. ABT: 4.63 )
ABT' s 10-Year ROA (%) Range
Min: 4.68   Max: 18.83
Current: 4.63

4.68
18.83
ROC (Joel Greenblatt) (%) 28.03
ABT's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. ABT: 28.03 )
ABT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 21.07   Max: 87.93
Current: 28.03

21.07
87.93
Revenue Growth (%) -15.00
ABT's Revenue Growth (%) is ranked higher than
53% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. ABT: -15.00 )
ABT' s 10-Year Revenue Growth (%) Range
Min: -15   Max: 12.6
Current: -15

-15
12.6
EBITDA Growth (%) -21.20
ABT's EBITDA Growth (%) is ranked higher than
60% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. ABT: -21.20 )
ABT' s 10-Year EBITDA Growth (%) Range
Min: -21.2   Max: 31.5
Current: -21.2

-21.2
31.5
EPS Growth (%) -20.40
ABT's EPS Growth (%) is ranked higher than
62% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ABT: -20.40 )
ABT' s 10-Year EPS Growth (%) Range
Min: -54   Max: 48.8
Current: -20.4

-54
48.8
» ABT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ABT Guru Trades in Q4 2013

Daniel Loeb 3,250,000 sh (New)
Jim Simons 871,800 sh (New)
Paul Tudor Jones 6,100 sh (New)
Mario Gabelli 197,183 sh (+110.21%)
Robert Olstein 179,000 sh (+23.45%)
Pioneer Investments 2,154,486 sh (+6.2%)
Bill Frels 351,373 sh (+3.69%)
Jeremy Grantham 16,154,651 sh (+0.78%)
John Buckingham 85,845 sh (+0.52%)
Diamond Hill Capital 3,088,381 sh (+0.2%)
Westport Asset Management 200,000 sh (unchged)
Jeff Auxier 80,490 sh (unchged)
Dodge & Cox 36,930 sh (unchged)
Tom Russo 86,503 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Ray Dalio Sold Out
PRIMECAP Management 16,135,908 sh (-0.33%)
Richard Pzena 6,426,564 sh (-0.35%)
Mason Hawkins 13,445,344 sh (-2.06%)
Robert Bruce 229,300 sh (-2.13%)
Murray Stahl 34,603 sh (-5.81%)
George Soros 970,181 sh (-7.97%)
Ken Fisher 7,645 sh (-9.41%)
Steven Cohen 5,622 sh (-90.74%)
» More
Q1 2014

ABT Guru Trades in Q1 2014

Louis Moore Bacon 10,998 sh (New)
Ray Dalio 17,200 sh (New)
Steven Cohen 156,100 sh (+2676.59%)
Diamond Hill Capital 5,984,714 sh (+93.78%)
George Soros 1,222,181 sh (+25.97%)
Ken Fisher 8,746 sh (+14.4%)
Richard Pzena 6,934,282 sh (+7.9%)
PRIMECAP Management 17,087,028 sh (+5.89%)
John Buckingham 88,280 sh (+2.84%)
Mason Hawkins 13,747,344 sh (+2.25%)
Robert Olstein 182,000 sh (+1.68%)
Jeremy Grantham 16,360,821 sh (+1.28%)
Murray Stahl 34,903 sh (+0.87%)
Dodge & Cox 36,950 sh (+0.05%)
Tom Russo 86,503 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Jeff Auxier 80,490 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Paul Tudor Jones Sold Out
Daniel Loeb Sold Out
Jim Simons Sold Out
Bill Frels 343,865 sh (-2.14%)
Pioneer Investments 2,002,948 sh (-7.03%)
Mario Gabelli 168,487 sh (-14.55%)
» More
Q2 2014

ABT Guru Trades in Q2 2014

Paul Tudor Jones 25,430 sh (New)
Jim Simons 1,503,700 sh (New)
Jean-Marie Eveillard 1,665,688 sh (New)
Ken Fisher 18,027 sh (+106.12%)
Diamond Hill Capital 6,422,284 sh (+7.31%)
Bill Frels 368,808 sh (+7.25%)
Richard Pzena 7,197,691 sh (+3.8%)
Ray Dalio 17,700 sh (+2.91%)
John Buckingham 89,447 sh (+1.32%)
PRIMECAP Management 17,127,063 sh (+0.23%)
Robert Olstein 182,000 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Louis Moore Bacon 200,000 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Tom Russo 86,503 sh (unchged)
Louis Moore Bacon 10,998 sh (unchged)
Dodge & Cox 36,898 sh (-0.14%)
Mason Hawkins 13,687,877 sh (-0.43%)
Pioneer Investments 1,990,174 sh (-0.64%)
Jeff Auxier 79,671 sh (-1.02%)
Murray Stahl 34,303 sh (-1.72%)
Mario Gabelli 160,707 sh (-4.62%)
George Soros 932,181 sh (-23.73%)
Jeremy Grantham 11,956,508 sh (-26.92%)
» More
Q3 2014

ABT Guru Trades in Q3 2014

Steven Cohen 200,000 sh (New)
Diamond Hill Capital 7,624,383 sh (+18.72%)
Dodge & Cox 39,628 sh (+7.4%)
Richard Pzena 7,287,523 sh (+1.25%)
John Buckingham 89,801 sh (+0.4%)
Robert Olstein 182,000 sh (unchged)
Tom Russo 86,503 sh (unchged)
Robert Bruce 229,300 sh (unchged)
Westport Asset Management 200,000 sh (unchged)
Vanguard Health Care Fund 7,591,400 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
Pioneer Investments 1,989,506 sh (-0.03%)
PRIMECAP Management 17,089,257 sh (-0.22%)
Jeff Auxier 79,371 sh (-0.38%)
Bill Frels 359,970 sh (-2.4%)
Mason Hawkins 12,483,566 sh (-8.8%)
Jean-Marie Eveillard 1,426,919 sh (-14.33%)
George Soros 797,181 sh (-14.48%)
Murray Stahl 29,303 sh (-14.58%)
Jeremy Grantham 10,155,603 sh (-15.06%)
Ken Fisher 11,261 sh (-37.53%)
Mario Gabelli 98,937 sh (-38.44%)
Paul Tudor Jones 8,170 sh (-67.87%)
Jim Simons 144,983 sh (-90.36%)
» More
» Details

Insider Trades

Latest Guru Trades with ABT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mason Hawkins 2014-09-30 Reduce -8.8%0.26%$41.05 - $43.69 $ 44.515%12483566
Ray Dalio 2014-09-30 Sold Out 0.01%$41.05 - $43.69 $ 44.515%0
Mario Gabelli 2014-09-30 Reduce -38.44%0.01%$41.05 - $43.69 $ 44.515%98937
Ken Fisher 2014-09-30 Reduce -37.53%$41.05 - $43.69 $ 44.515%11261
Jean-Marie Eveillard 2014-06-30 New Buy0.16%$37.02 - $41 $ 44.5113%1665688
George Soros 2014-06-30 Reduce -23.73%0.11%$37.02 - $41 $ 44.5113%932181
Ken Fisher 2014-06-30 Add 106.12%$37.02 - $41 $ 44.5113%18027
Daniel Loeb 2014-03-31 Sold Out 2.1%$35.85 - $40.12 $ 44.5116%0
Richard Pzena 2014-03-31 Add 7.9%0.11%$35.85 - $40.12 $ 44.5116%6934282
George Soros 2014-03-31 Add 25.97%0.1%$35.85 - $40.12 $ 44.5116%1222181
Ray Dalio 2014-03-31 New Buy0.01%$35.85 - $40.12 $ 44.5116%17200
Daniel Loeb 2013-12-31 New Buy2.1%$33.01 - $38.71 $ 44.5121%3250000
Robert Olstein 2013-12-31 Add 23.45%0.19%$33.01 - $38.71 $ 44.5121%179000
Ray Dalio 2013-12-31 Sold Out 0.03%$33.01 - $38.71 $ 44.5121%0
Mario Gabelli 2013-12-31 Add 110.21%0.02%$33.01 - $38.71 $ 44.5121%197183
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Abbott Laboratories

Lountzis Asset Management Comments on Abbott Laboratories - Mar 21, 2014

ABBOTT LABORATORIES (ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products.



On January 1, 2013, Abbott consummated the separation of its research based pharmaceuticals business and distributed 100% of the outstanding shares of common stock of AbbVie to the holders of record of Abbott common shares that were issued and outstanding on December 12, 2012. Each Abbot shareholder received one share of AbbVie common stock for every share of Abbot common stock held. The Abbott shareholder also received cash in lieu of any fractional share of AbbVie common stock resulting from the distribution.



Abbott common shares now trade under ticker symbol "ABT" and shares of AbbVie common stock trade under ticker symbol "ABBV". The new Abbott is a diversified global healthcare company with several leading franchises. In 2012, the company generated sales of $21.5 billion from these four diverse business units: nutritionals 30%, medical products 25%, established pharmaceuticals 24% and diagnostics 20%.



Abbott has leading market share positions in several businesses including the number one market share in:



1. Worldwide Adult Nutrition and U.S. Pediatric Nutrition



2. Amino Acid Immunoassay Diagnostics and Blood Screening



3. Drug Eluting Stents and for



4. Lasik



Furthermore, Abbott, in addition to a broad portfolio of products and services, is geographically diverse with 29% of sales in the U.S., 30% in other developed markets and 40% in the more rapidly growing emerging markets. The current Chairman and CEO, Miles D. White, will continue in these positions for the new Abbott, focused upon several initiatives including expanding the company’s products into new geographic markets, developing new technologies and focusing on accelerating margin expansion and improving free cash flow.



The new Abbott generated 2013 revenue through its four segments of $21.9 billion with earnings per share of $2.01. We continue to hold the new Abbott and believe its product and geographic diversity, combined with its leadership positions in several areas, will enable the company to continue to grow and prosper.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Diamond Hill Capital Comments on Abbott Laboratories - Jan 15, 2014

Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently.

From Diamond Hill Capital (Trades, Portfolio) Large Cap Fund third quarter 2013 commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Abbott Laboratories

Lountzis Asset Management Comments on Abbott Laboratories
ABBOTT LABORATORIES (ABT) is a leading diversified healthcare company operating in the following areas: pharmaceuticals, diagnostics, nutritionals and medical products. Read more...
Diamond Hill Capital Comments on Abbott Laboratories
Drug manufacturer Abbott Laboratories (ABT) reported revenue growth that was below expectations due to its exposure to the slower growth economies in Europe and the emerging markets. Despite the recent weakness, Abbott is a high-quality company with shares that we believe to be attractively priced. In addition, its management team has a strong record of investing capital prudently. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 35.00
ABT's P/E(ttm) is ranked higher than
82% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 106.60 vs. ABT: 35.00 )
ABT' s 10-Year P/E(ttm) Range
Min: 5.76   Max: 34.68
Current: 35

5.76
34.68
P/B 2.90
ABT's P/B is ranked higher than
75% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. ABT: 2.90 )
ABT' s 10-Year P/B Range
Min: 1.39   Max: 3.06
Current: 2.9

1.39
3.06
P/S 3.00
ABT's P/S is ranked higher than
72% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. ABT: 3.00 )
ABT' s 10-Year P/S Range
Min: 0.96   Max: 2.95
Current: 3

0.96
2.95
PFCF 23.40
ABT's PFCF is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABT: 23.40 )
ABT' s 10-Year PFCF Range
Min: 4.38   Max: 30.6
Current: 23.4

4.38
30.6
EV-to-EBIT 22.88
ABT's EV-to-EBIT is ranked higher than
82% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. ABT: 22.88 )
ABT' s 10-Year EV-to-EBIT Range
Min: 6.7   Max: 29.7
Current: 22.88

6.7
29.7
Shiller P/E 14.80
ABT's Shiller P/E is ranked higher than
97% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABT: 14.80 )
ABT' s 10-Year Shiller P/E Range
Min: 8.21   Max: 15.05
Current: 14.8

8.21
15.05
Current Ratio 1.52
ABT's Current Ratio is ranked higher than
54% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. ABT: 1.52 )
ABT' s 10-Year Current Ratio Range
Min: 0.75   Max: 2.36
Current: 1.52

0.75
2.36
Quick Ratio 1.27
ABT's Quick Ratio is ranked higher than
58% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. ABT: 1.27 )
ABT' s 10-Year Quick Ratio Range
Min: 0.55   Max: 2.07
Current: 1.27

0.55
2.07

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.00
ABT's Dividend Yield is ranked higher than
72% of the 185 Companies
in the Global Medical Devices industry.

( Industry Median: 1.37 vs. ABT: 2.00 )
ABT' s 10-Year Dividend Yield Range
Min: 1.41   Max: 7.9
Current: 2

1.41
7.9
Dividend Payout 0.63
ABT's Dividend Payout is ranked higher than
98% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABT: 0.63 )
ABT' s 10-Year Dividend Payout Range
Min: 0.23   Max: 2.53
Current: 0.63

0.23
2.53
Dividend growth (3y) -31.20
ABT's Dividend growth (3y) is ranked higher than
62% of the 104 Companies
in the Global Medical Devices industry.

( Industry Median: 8.90 vs. ABT: -31.20 )
ABT' s 10-Year Dividend growth (3y) Range
Min: -31.2   Max: 12.6
Current: -31.2

-31.2
12.6
Yield on cost (5-Year) 0.77
ABT's Yield on cost (5-Year) is ranked lower than
71% of the 187 Companies
in the Global Medical Devices industry.

( Industry Median: 1.57 vs. ABT: 0.77 )
ABT' s 10-Year Yield on cost (5-Year) Range
Min: 0.55   Max: 3.06
Current: 0.77

0.55
3.06
Share Buyback Rate -0.40
ABT's Share Buyback Rate is ranked higher than
84% of the 332 Companies
in the Global Medical Devices industry.

( Industry Median: -1.40 vs. ABT: -0.40 )
ABT' s 10-Year Share Buyback Rate Range
Min: 1   Max: -0.8
Current: -0.4

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 9.87
ABT's Price/Tangible Book is ranked higher than
62% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. ABT: 9.87 )
ABT' s 10-Year Price/Tangible Book Range
Min: 2.98   Max: 427.6
Current: 9.87

2.98
427.6
Price/DCF (Projected) 0.93
ABT's Price/DCF (Projected) is ranked higher than
97% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABT: 0.93 )
ABT' s 10-Year Price/DCF (Projected) Range
Min: 0.36   Max: 2.25
Current: 0.93

0.36
2.25
Price/Median PS Value 2.00
ABT's Price/Median PS Value is ranked higher than
59% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. ABT: 2.00 )
ABT' s 10-Year Price/Median PS Value Range
Min: 0.67   Max: 1.89
Current: 2

0.67
1.89
Price/Graham Number 3.72
ABT's Price/Graham Number is ranked higher than
79% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ABT: 3.72 )
ABT' s 10-Year Price/Graham Number Range
Min: 1.07   Max: 20.86
Current: 3.72

1.07
20.86
Earnings Yield (Greenblatt) 4.40
ABT's Earnings Yield (Greenblatt) is ranked higher than
82% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. ABT: 4.40 )
ABT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.4   Max: 15
Current: 4.4

3.4
15
Forward Rate of Return (Yacktman) -7.25
ABT's Forward Rate of Return (Yacktman) is ranked higher than
63% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. ABT: -7.25 )
ABT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.3   Max: 33.6
Current: -7.25

-7.3
33.6

Business Description

Industry: Medical Devices » Medical Devices
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:ABT.UK, ABT.Switzerland, ABL.Germany, ABTT34.Brazil, ABT.Mexico, ABT.Argentina
Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells health care products. Its services are sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians' offices and government agencies internationally.Its segments are Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Vascular Product. The Established Pharmaceutical Products is engaged in the International sales of various branded generic pharmaceutical products. Nutritional Products sells broad line of adult and pediatric nutritional products internationally. Diagnostic Products sells diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. This segment also includes Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions. Vascular Products sells f coronary, endovascular, structural heart, vessel closure and other medical device products.
» More Articles for ABT

Headlines

Articles On GuruFocus.com
Dividend Aristocrats In Focus Part 45: AbbVie Nov 24 2014 
Dividend Aristocrats In Focus Part 41: Abbott Laboratories (ABT) Nov 17 2014 
Sure Bets: Slow-Changing Industries for Long-Term Investors Oct 01 2014 
Market Indicators That Could Spell Trouble for Investors Sep 29 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
Baxter Will Remain Diversified and With Competitive Advantages Sep 02 2014 
Abbott: A Brighter Future Aug 28 2014 
6 Stocks Currently Trading Below Fair Value Jul 02 2014 
Why I Bought Baxter International Jun 19 2014 


More From Other Websites
Appointment of a Non-Executive Director Nov 19 2014
Zoetis 2015 Guidance Misses As Buyout Theories Abound Nov 18 2014
People with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the... Nov 17 2014
[$$] Zoetis to Buy Abbott's Animal Health Assets Nov 17 2014
Extended anti-clotting therapy cut heart attacks after stent -study Nov 16 2014
Big Study Looks At Length of Drug Treatment After Stent Implantation Nov 16 2014
Abbott Laboratories (ABT) Showing Signs Of Being Water-Logged And Getting Wetter Nov 14 2014
ABBOTT LABORATORIES Financials Nov 14 2014
Today's Market Overview. Nov 13 2014
10-Q for Abbott Laboratories Nov 08 2014
ABBOTT LABORATORIES Files SEC form 10-Q, Quarterly Report Nov 06 2014
India vs. China: The Battle for Global Manufacturing Nov 06 2014
Abbott to Present at Credit Suisse 2014 Healthcare Conference Nov 04 2014
Smith & Nephew's Bohuon seen as strong candidate for top Sanofi job Nov 04 2014
Smith & Nephew's Bohuon seen as strong candidate for top Sanofi job Nov 04 2014
Mylan Rises On Q3 Earnings Beat, Affirms Abbott Deal Oct 31 2014
Abbott’s three big heart deals have one thing in common Oct 30 2014
Abbott Labs Pays $250 Million for Topera in Heart Health Move Oct 30 2014
Abbott Labs Pays $250 Million for Topera in Heart Health Move Oct 30 2014
INDIA PRESS-Johnson & Johnson may buy electrolyte drink ORS-L for 7 bln rupees - Times of India Oct 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK